ISSN: 1859 - 2872
Long-term survival of residual hepatocellular carcinoma patients after chemoembolization treated with stereotactic body radiation therapy
Main Article Content
Keywords
Abstract
Objective: To evaluate long-term survival of residual hepatocellular carcinoma patients after Transarterial Chemoembolization (TACE) treated with Stereotactic Body Radiation Therapy (SBRT). Subject and method: A prospective, controlled intervention study on 42 patients with hepatocellular carcinoma (HCC) treated with SBRT and 38 patients treated with TACE using DC Beads. Evaluation of survival by Kaplan Meier curve and Log Rank test. Result: The mean follow-up time was 16.1 ± 7.5 months (4.0-34.2 months). The overall survival time of patients after SBRT (27.67 ± 1.77 months) was different from that after TACE (18.86 ± 1.52 months). The overall survival rates at 12, 24, and 30 months after SBRT were 84.1%, 74.1%, and 68.8%, respectively, with a difference compared with after TACE of 69.4%, 37.9%, 37.9%, respectively. Kinki stage B2, liver tumor size group ≥ 5cm were significantly longer predictors of overall survival after SBRT than after TACE. Conclusion: SBRT is a method with a higher long-term survival outcome than repeat TACE for residual HCC patients after TACE.
Article Details
References
2. Nouri YM, Kim JH, Yoon HK et al (2019) Update on transarterial chemoembolization with drug-eluting microspheres for hepatocellular carcinoma. Korean J Radiol 20(1): 34-49.
3. Zhong BY, Wang WS, Zhang S et al (2021) Re-evaluating transarterial chemoembolization failure/refractoriness: A survey by chinese college of interventionalists. J Clin Transl Hepatol 9(4): 521-527.
4. Schaub SK, Hartvigson PE, Lock MI et al (2018) Stereotactic body radiation therapy for hepatocellular carcinoma: Current trends and controversies. Technol Cancer Res Treat 17: 1533033818790217.
5. Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 68(2): 723-750.
6. Jacob R, Turley F, Redden DT et al (2015) Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3cm. HPB (Oxford) 17(2): 140-149.
7. Yao E, Chen J, Zhao X et al (2018) Efficacy of stereotactic body radiotherapy for recurrent or residual hepatocellular carcinoma after transcatheter arterial chemoembolization. Biomed Res Int 2018: 5481909.
8. Thái Doãn Kỳ, Mai Hồng Bàng, Phạm Minh Thông và cộng sự (2016) Nghiên cứu kết quả điều trị ung thư biểu mô tế bào gan bằng phương pháp tắc mạch hóa chất sử dụng hạt vi cầu DC BEADS. Luận án Tiến sĩ y học, Viện Nghiên cứu Khoa học Y Dược lâm sàng 108.
9. Nguyễn Tiến Thịnh, Mai Hồng Bàng, Thái Doãn Kỳ và cộng sự (2016) Kết quả điều trị ung thư biểu mô tế bào gan kích thước trên 3cm bằng phương pháp tắc mạch hóa dầu kết hợp đốt nhiệt sóng cao tần. Tạp chí Y Dược lâm sàng 108, Tập 11, tr. 232-238.
10. Kang JK, Kim MS, Cho CK et al (2012) Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 118(21): 5424-5431.
Article Sidebar
